Silo Pharma Inc. (NASDAQ: SILO) announced that its wholly owned managed AI agent subsidiary, QwikAgents, has expanded its platform with support for customer-supplied NVIDIA API keys and the addition of the Hermes agent runtime. This development matters because it gives enterprises greater control over their AI infrastructure and reduces vendor lock-in, a critical consideration as companies scale their AI operations.
Customers can now use their own NVIDIA API keys to access NVIDIA Nemotron models, making NVIDIA the fifth supported bring-your-own-key provider alongside Anthropic, OpenAI, Google, and DeepSeek. This bring-your-own-key model allows organizations to leverage existing contracts, manage costs more effectively, and maintain compliance with internal procurement policies. By integrating NVIDIA, a leader in accelerated computing and AI, QwikAgents positions itself as a flexible platform that can adapt to diverse enterprise needs.
In addition to NVIDIA support, QwikAgents added Hermes as an alternative to OpenClaw runtime, allowing customers to select either option when creating an AI agent. Both runtimes operate on QwikAgents infrastructure, which includes managed hosting, persistent memory, model routing, and dedicated compute. This dual-runtime approach provides customers with the ability to choose the runtime that best fits their performance, cost, and compatibility requirements, without sacrificing the benefits of a fully managed service.
The implications of these enhancements are significant for the AI agent market. As businesses increasingly deploy autonomous agents for tasks ranging from customer service to data analysis, the need for customizable, secure, and scalable solutions grows. QwikAgents' expansion addresses these needs by offering a managed environment that supports multiple model providers and runtimes, thereby reducing the complexity of building and maintaining AI agents. This could accelerate adoption across industries that have been hesitant to embrace AI due to integration challenges or concerns about data sovereignty.
For Silo Pharma, a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, the QwikAgents update represents a strategic move to diversify its portfolio beyond therapeutics. While Silo Pharma's core focus remains on addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases, its foray into AI through QwikAgents demonstrates a broader vision. The company's therapeutic programs include SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis.
To view the full press release, visit https://ibn.fm/AXpqr. The latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO.
About AINewsWire: AINewsWire ("AINW") is a specialized communications platform with a focus on the latest advancements in artificial intelligence, including the technologies, trends, and trailblazers driving innovation forward. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
